Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53

(2013) M. A. Gadhikar et al.   MOLECULAR CANCER THERAPEUTICS

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

(2012) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

(2012) Luis Paz-Ares et al.   LANCET ONCOLOGY

Abstract B248: Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials

(2012) M. Marshall et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

(2011) M Bartucci et al.   CELL DEATH AND DIFFERENTIATION

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

Targeting the checkpoint kinase Chk1 in cancer therapy

(2010) Callie Merry et al.   CELL CYCLE

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

(2010) M. I. Walton et al.   MOLECULAR CANCER THERAPEUTICS

Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

(2009) J. M. Wagner et al.   MOLECULAR PHARMACOLOGY

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS